These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 9816008)

  • 1. Induction and maintenance of monocyte cytotoxicity during treatment with liposomes containing muramyl tripeptide despite tachyphylaxis to the cytokine response.
    Galligioni E; Favaro D; Santarosa M; Quaia M; Spada A; Freschi A; Alberti D
    Clin Cancer Res; 1995 May; 1(5):493-9. PubMed ID: 9816008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.
    Liebes L; Walsh CM; Chachoua A; Oratz R; Richards D; Hochster H; Peace D; Marino D; Alba S; Le Sher D
    J Natl Cancer Inst; 1992 May; 84(9):694-9. PubMed ID: 1569602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
    J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
    Maeda M; Knowles RD; Kleinerman ES
    Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble intercellular adhesion molecule-1 and serum cytokines in melanoma patients treated with liposomes containing muramyl tripeptide.
    Favaro D; Santarosa M; Quaia M; Spada A; Freschi A; Talamini R; Galligioni E
    Tumori; 1995; 81(3):185-90. PubMed ID: 7571025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid).
    Fujimaki W; Itoh K; An T; Gano JB; Ross MI; Mansfield PF; Balch CM; Augustus LB; Karkevitch DD; Johnston D
    Cancer Biother; 1993; 8(4):307-18. PubMed ID: 7804372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
    Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
    Fujimaki W; Griffin JR; Kleinerman ES
    Cancer Immunol Immunother; 1993; 36(1):45-51. PubMed ID: 8422667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.
    Tandon P; Utsugi T; Sone S
    Cancer Res; 1986 Oct; 46(10):5039-44. PubMed ID: 3489519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.
    Urba WJ; Hartmann LC; Longo DL; Steis RG; Smith JW; Kedar I; Creekmore S; Sznol M; Conlon K; Kopp WC
    Cancer Res; 1990 May; 50(10):2979-86. PubMed ID: 1692252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in normal cats.
    Fox LE; King RR; Shi F; Kurzman ID; MacEwen EG; Kubilis PS
    Cancer Biother; 1994; 9(4):329-40. PubMed ID: 7719380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide.
    Landmann R; Obrist R; Denz H; Ludwig C; Frost H; Wesp M; Rordorf C; Towbin H; Gygax D; Tarcsay L
    Biotherapy; 1993; 7(1):1-12. PubMed ID: 8068481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.
    Maeda M; Asano T; Kleinerman ES
    Cancer Immunol Immunother; 1993 Aug; 37(3):203-8. PubMed ID: 8334682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
    Shi F; MacEwen EG; Kurzman ID
    Cancer Res; 1993 Sep; 53(17):3986-91. PubMed ID: 8358727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine.
    Kleinerman ES; Murray JL; Snyder JS; Cunningham JE; Fidler IJ
    Cancer Res; 1989 Aug; 49(16):4665-70. PubMed ID: 2787207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
    Kleinerman ES; Maeda M; Jaffe N
    Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
    Asano T; Kleinerman ES
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs.
    Bezault J; Walsh C; Tarcsay L; Frost H; Liebes L; Furmanski P
    In Vivo; 1993; 7(6A):487-91. PubMed ID: 8193265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression.
    Asano T; Fujimaki W; McWatters A; An T; Matsushima K; Kleinerman ES
    Cancer Immunol Immunother; 1993 Nov; 37(6):408-11. PubMed ID: 8242665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.